Genetic factors influencing the development of vincristine-induced neurotoxicity

References

• van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Crit Rev Oncol Hematol. 2017 Jun;114:114–130.
   PubMed Web of Science ®Google Scholar
• Yang L, Yu L, Chen X, et al. Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med Sci Monit. 2015 Jun;21:1656–1661.
   PubMed Web of Science ®Google Scholar
• Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):483–494.
   PubMed Web of Science ®Google Scholar
• Khalilzadeh M, Panahi G, Rashidian A, et al. The protective effects of sumatriptan on vincristine - induced peripheral neuropathy in a rat model. Neurotoxicology. Jul 2018;67: 279–286.
   PubMed Web of Science ®Google Scholar
• Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996 May;35(21):6806–6814.
   PubMed Web of Science ®Google Scholar
• Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol. 1986 Nov-Dec;1(6):421–427.
   PubMedGoogle Scholar
• Mora E, Smith EM, Donohoe C, et al. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016;6(11):2416–2430.
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015 Mar;20(1):37–46.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Marais L, Tanner L. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer. 2014 Feb;22(2):359–366.
   PubMed Web of Science ®Google Scholar
• Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15–49.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Polychronopoulos P, Koutras A, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006 Mar;14(3):223–229.
   PubMed Web of Science ®Google Scholar
• Courtemanche H, Magot A, Ollivier Y, et al. Vincristine-induced neuropathy: atypical electrophysiological patterns in children. Muscle Nerve. 2015 Dec;52(6):981–985.
   PubMed Web of Science ®Google Scholar
• Madsen ML, Due H, Ejskjær N, et al. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019 Sep;84(3):471–485.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011 Nov;12(12):1151–1161.
   PubMed Web of Science ®Google Scholar
• Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. Methods Mol Biol. 2014;1175:301–322.
   PubMedGoogle Scholar
• Kawakami K, Tunoda T, Takiguchi T, et al. Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncol Res. 2012;20(4):179–185.
   PubMed Web of Science ®Google Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461–2470.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest oncology group clinical trials. J Clin Oncol. 2016 Sep;34(25):3014–3022.
   PubMed Web of Science ®Google Scholar
• Mielke S. Individualized pharmacotherapy with paclitaxel. Curr Opin Oncol. 2007 Nov;19(6):586–589.
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10–16.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Genazzani AA, et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017 Aug;13(8):492–504.
   PubMed Web of Science ®Google Scholar
• Saba N, Bhuyan R, Nandy SK, et al. Differential interactions of cytochrome P450 3A5 and 3A4 with chemotherapeutic agent-vincristine: a comparative molecular dynamics study. Anticancer Agents Med Chem. 2015;15(4):475–483.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006 Aug;34(8):1317–1327.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 Apr;27(4):383–391.
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004 Apr;5(3):243–272.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007 May;321(2):553–563.
   PubMed Web of Science ®Google Scholar
• Dennison JB, Mohutsky MA, Barbuch RJ, et al. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther. 2008 Oct;327(1):248–257.
   PubMed Web of Science ®Google Scholar
• Saba N, Seal A. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5. J Mol Model. 2018 Mar;24(4):82.
   PubMed Web of Science ®Google Scholar
• Kayilioğlu H, Kocak U, Kan Karaer D, et al. Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458–462.
   PubMed Web of Science ®Google Scholar
• Moore A, Pinkerton R. Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer. 2009 Dec;53(7):1180–1187.
   PubMed Web of Science ®Google Scholar
• Sims RP. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016 Feb;22(1):76–81.
   PubMedGoogle Scholar
• Bosilkovska M, Ing Lorenzini K, Uppugunduri CR, et al. Severe vincristine-induced neuropathic pain in a CYP3A5 nonexpressor with reduced CYP3A4/5 activity: case study. Clin Ther. 2016 Jan;38(1):216–220.
   PubMed Web of Science ®Google Scholar
• Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008 Apr;50(4):769–771.
   PubMed Web of Science ®Google Scholar
• Chan A, Hertz DL, Morales M, et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer. 2019 Oct;27(10):3729–3737.
   PubMed Web of Science ®Google Scholar
• Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Mar;56(3):361–367.
   PubMed Web of Science ®Google Scholar
• Guilhaumou R, Solas C, Bourgarel-Rey V, et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol. 2011 Dec;68(6):1633–1638.
   PubMed Web of Science ®Google Scholar
• McClain CA, Bernhardt MB, Berger A, et al. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia. Br J Haematol. 2018 Jun;181(5):684–687.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003 Jul;122(2):240–244.
   PubMed Web of Science ®Google Scholar
• Ceppi F, Langlois-Pelletier C, Gagné V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun;15(8):1105–1116.
   PubMed Web of Science ®Google Scholar
• Hartman A, van Schaik RH, van der Heiden IP, et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res. 2010 Feb;34(2):154–159.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016 May;17(7):731–741.
   PubMed Web of Science ®Google Scholar
• Moore AS, Norris R, Price G, et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health. 2011 Dec;47(12):875–882.
   PubMed Web of Science ®Google Scholar
• Wright GEB, Amstutz U, Drögemöller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019 Feb;105(2):402–410.
   PubMed Web of Science ®Google Scholar
• Sawaki A, Miyazaki K, Yamaguchi M, et al. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. Int J Hematol. 2020 May;111(5):686–691.
   PubMed Web of Science ®Google Scholar
• Skiles JL, Chiang C, Li CH, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. 2018 Mar;65(3).
   Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007 May;109(10):4151–4157.
   PubMed Web of Science ®Google Scholar
• Becker PS. Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma. J Clin Oncol. 2011 Mar;29(7):783–786.
   PubMed Web of Science ®Google Scholar
• Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014 Aug;40(7):872–882.
   PubMed Web of Science ®Google Scholar
• Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar;29(7):797–804.
   PubMed Web of Science ®Google Scholar
• Islam B, Lustberg M, Staff NP, et al. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019 Oct;24(Suppl 2):S63–S73.
   PubMedGoogle Scholar
• Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012 Jul;55(4):290–297.
   PubMed Web of Science ®Google Scholar
• Huang R, Murry DJ, Kolwankar D, et al. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006 Jun;71(12):1695–1704.
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Ghanem KM, Tamim H, et al. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 Aug;28(8):189–195.
   PubMed Web of Science ®Google Scholar
• Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Á G-C, Umerez M, Martin-Guerrero I, et al. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J. 2018 Dec;18(6):704–712.
   PubMed Web of Science ®Google Scholar
• Kandula T, Park SB, Cohn RJ, et al. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treat Rev. 2016 Nov;50:118–128.
   PubMed Web of Science ®Google Scholar
• Oshimori N, Li X, Ohsugi M, et al. Cep72 regulates the localization of key centrosomal proteins and proper bipolar spindle formation. Embo J. 2009 Jul;28(14):2066–2076.
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015 Feb;313(8):815–823.
   PubMed Web of Science ®Google Scholar
• Stock W, Diouf B, Crews KR, et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2017 Mar;101(3):391–395.
   PubMed Web of Science ®Google Scholar
• Li L, Sajdyk T, Smith EML, et al. Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2019 Jun;105(6):1421–1428.
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Evans WE. Vincristine pharmacogenomics: ‘winner’s curse’ or a different phenotype? Pharmacogenet Genomics. 2016 Feb;26(2):51–52.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2016 Feb;26(2):100–102.
   PubMed Web of Science ®Google Scholar
• Hubert T, Van Impe K, Vandekerckhove J, et al. The actin-capping protein CapG localizes to microtubule-dependent organelles during the cell cycle. Biochem Biophys Res Commun. 2009 Feb;380(1):166–170.
   PubMed Web of Science ®Google Scholar
• Verrills NM, Liem NL, Liaw TY, et al. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia–an in vivo study. Proteomics. 2006 Mar;6(5):1681–1694.
   PubMed Web of Science ®Google Scholar
• Lee CG, Jang J, Jin HS. A novel missense mutation in the ACTG1 gene in a family with congenital autosomal dominant deafness: a case report. Mol Med Rep. 2018 Jun;17(6):7611–7617.
   PubMed Web of Science ®Google Scholar
• Abaji R, Ceppi F, Patel S, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018 Oct;19(15):1181–1193.
   PubMed Web of Science ®Google Scholar
• Rajgor D, Shanahan CM. Nesprins: from the nuclear envelope and beyond. Expert Rev Mol Med. 2013 Jul;15:e5.
   PubMed Web of Science ®Google Scholar
• Martin-Guerrero I, Gutierrez-Camino A, Echebarria-Barona A, et al. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2019 Dec;19(6):564–569.
   PubMed Web of Science ®Google Scholar
• Hogan-Dann CM, Fellmeth WG, McGuire SA, et al. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA. 1984 Nov 23-30;252(20):2862–2863.
   PubMed Web of Science ®Google Scholar
• Olek MJ, Bordeaux B, Leshner RT. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis. J Am Osteopath Assoc. 1999 Mar;99(3):165–167.
   PubMedGoogle Scholar
• Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003 Apr;25(4):316–320.
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Suzuki D, Inamoto J, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012 Apr;34(3):239–241.
   PubMed Web of Science ®Google Scholar
• Arora RD, Menezes RG Vinca alkaloid toxicity. StatPearls [Internet]. 2020 Sep.
   Google Scholar
• Trobaugh-Lotrario AD, Smith AA, Odom LF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol. 2003 Jan;40(1):39–43.
   PubMedGoogle Scholar
• Bahl A, Chakrabarty B, Gulati S, et al. Acute onset flaccid quadriparesis in pediatric non-Hodgkin lymphoma: vincristine induced or Guillain-Barré syndrome? Pediatr Blood Cancer. 2010 Dec;55(6):1234–1235.
   PubMed Web of Science ®Google Scholar
• Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000 Oct;34(10):1136–1138.
   PubMed Web of Science ®Google Scholar